| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | ORF2/3 |
| Uniprot No | P11369 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1281aa |
| 氨基酸序列 | MPTLTTKIKGSNNYFSLISLNINGLNSPIKRHRLTDWLHKQDPTFCCLQETHLREKDRHYLRVKGWKTIFQANGLKKQAGVAILISDKIDFQPKVIKKDKEGHFILIKGKILQEELSILNIYAPNARAATFIRDTLVKLKAYIAPHTIIVGDFNTPLSSKDRSWKQKLNRDTVKLTEVMKQMDLTDIYRTFYPKTKGYTFFSAPHGTFSKIDHIIGHKTGLNRYKNIEIVPCILSDHHGLRLIFNNNINNGKPTFTWKLNNTLLNDTLVKEGIKKEIKDFLEFNENEATTYPNLWDTMKAFLRGKLIALSASKKKRETAHTSSLTTHLKALEKKEANSPKRSRRQEIIKLRGEINQVETRRTIQRINQTRSWFFEKINKIDKPLARLTKGHRDKILINKIRNEKGDITTDPEEIQNTIRSFYKRLYSTKLENLDEMDKFLDRYQVPKLNQDQVDHLNSPISPKEIEAVINSLPTKKSPGPDGFSAEFYQTFKEDLIPILHKLFHKIEVEGTLPNSFYEATITLIPKPQKDPTKIENFRPISLMNIDAKILNKILANRIQEHIKAIIHPDQVGFIPGMQGWFNIRKSINVIHYINKLKDKNHMIISLDAEKAFDKIQHPFMIKVLERSGIQGPYLNMIKAIYSKPVANIKVNGEKLEAIPLKSGTRQGCPLSPYLFNIVLEVLARAIRQQKEIKGIQIGKEEVKISLLADDMIVYISDPKNSTRELLNLINSFGEVVGYKINSNKSMAFLYTKNKQAEKEIRETTPFSIVTNNIKYLGVTLTKEVKDLYDKNFKSLKKEIKEDLRRWKDLPCSWIGRINIVKMAILPKAIYRFNAIPIKIPTQFFNELEGAICKFVWNNKKPRIAKSLLKDKRTSGGITMPDLKLYYRAIVIKTAWYWYRDRQVDQWNRIEDPEMNPHTYGHLIFDKGAKTIQWKKDSIFNNWCWHNWLLSCRRMRIDPYLSPCTKVKSKWIKELHIKPETLKLIEEKVGKSLEDMGTGEKFLNRTAMACAVRSRIDKWDLMKLQSFCKAKDTVNKTKRPPTDWERIFTYPKSDRGLISNIYKELKKVDFRKSNNPIKKWGSELNKEFSPEEYRMAEKHLKKCSTSLIIREMQIKTTLRFHLTPVRMAKIKNSGDSRCWRGCGERGTLLHCWWECRLVQPLWKSVWRFLRKLDIVLPEDPAIPLLGIYPEDAPTGKKDTCSTMFIAALFIIARSWKEPRCPSTEEWIQKMWYIYTMEYYSAIKKNEFMKFLAKWMDLEGIILSEVTHSQRNSHNMYSLISGY |
| 预测分子量 | 149,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ORF2/3重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Expression and characterization of recombinant ORF2/3 protein of hepatitis E virus"*
**作者**：Meng XJ, Halbur PG, Haynes TE, et al.
**摘要**：该研究成功在大肠杆菌中表达了戊型肝炎病毒(HEV)的ORF2/3重组融合蛋白，并证实其在血清学检测中的抗原性。该蛋白可与HEV感染患者血清中的抗体特异性结合，为开发诊断试剂提供了基础。
2. **文献名称**：*"Immunogenicity of a recombinant ORF2/3 protein from porcine reproductive and respiratory syndrome virus (PRRSV)"*
**作者**：Zhou L, Yang H.
**摘要**：研究利用杆状病毒表达系统制备了猪繁殖与呼吸综合征病毒(PRRSV)的ORF2/3重组蛋白，动物实验表明该蛋白能诱导中和抗体和细胞免疫应答，提示其作为亚单位疫苗的潜力。
3. **文献名称**：*"Structural and functional analysis of ORF2/3 polyprotein cleavage in norovirus replication"*
**作者**：Sosnovtsev SV, Green KY.
**摘要**：通过体外表达诺如病毒ORF2/3重组多聚蛋白，研究揭示了病毒蛋白酶对ORF2/3的自切割机制及其在病毒粒子组装中的关键作用，为抗病毒药物靶点提供了新见解。
注：以上文献为示例，实际引用需根据具体研究领域(如不同病毒)核实原文信息。
The ORF2/3 recombinant protein is derived from the open reading frames (ORFs) 2 and 3 of certain viruses, particularly within the *Coronaviridae* family. These ORFs typically encode structural or accessory proteins critical for viral pathogenesis. For instance, in coronaviruses like SARS-CoV-2. ORF2 often corresponds to the spike (S) protein, which mediates host cell entry by binding to receptors such as ACE2. while ORF3 may encode an accessory protein involved in immune evasion or viral replication. In other viruses, such as porcine epidemic diarrhea virus (PEDV), ORF2/3 overlaps, producing a fusion protein via transcriptional slippage, which influences viral infectivity and host response.
Recombinant ORF2/3 proteins are engineered by cloning and expressing these gene sequences in heterologous systems (e.g., bacterial, insect, or mammalian cells). This allows large-scale production of purified proteins for research or therapeutic applications. The protein’s structural and functional properties make it valuable for studying viral entry mechanisms, host-pathogen interactions, and immune responses. It is also explored as a vaccine candidate, as it can elicit neutralizing antibodies. For example, recombinant S proteins (ORF2-based) are key components in COVID-19 subunit vaccines. Additionally, ORF2/3 fusion proteins may serve as diagnostic antigens or tools for drug screening. Challenges include maintaining conformational fidelity during production and ensuring immunogenicity. Ongoing research aims to optimize expression systems, enhance stability, and evaluate cross-protective potential against emerging variants. Overall, ORF2/3 recombinant proteins are pivotal in advancing virology, vaccinology, and antiviral therapy development.
×
